Sector News

Bigger pharma may be scraping for good deals, but Horizon has plenty of options, analysts say

June 29, 2015
Life sciences
Horizon Pharma isn’t exactly the only specialty pharma company hunting for deals. Allergan, Mallinckrodt, Endo and the ever-acquisitive Valeant have all been on shopping sprees lately, leaving some analysts wondering just what’s left worth buying in the space. But Horizon is much smaller than its specialty peers–meaning it’s got plenty of opportunities, UBS analysts figure.
 
In a research report seen by Investor’s Business Daily, UBS’ Marc Goodman and Ami Fadia pointed out that Horizon–with a market cap just over $5 billion–is at least $9 billion smaller than other on-the-prowl specialty pharmas, meaning it’s “playing in a different sandbox.”
 
Because of its track record and balance sheet, Horizon “has hit the radar of more potential sellers of assets,” leading the analysts to up both their price target on the company’s stock and their revenue estimates.
 
That’s music to the ears of CEO Timothy Walbert, who has said he’s building up Horizon’s leadership and infrastructure “to support a larger organization,” the UBS analysts wrote. Recently, that’s involved foraying into the orphan-drug business with a pickup of osteoporosis treatment Actimmune–and following that up with May’s $1.1 billion acquisition of orphan drugmaker Hyperion.
 
And while it may have once looked like Horizon would need new offerings to fill in for Vimovo and Duexis–a pair of flagship products Express Scripts and CVS booted off their preferred formulary lists last year–sales of those drugs have held up, IBD notes, meaning pickups can only boost things further. The analysts credit that to the company’s “prescriptions made easy” sales method, one they say is “really the key differentiating piece for Horizon.”
 
By Carly Helfand
 

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach